News

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
The latest trading day saw Moderna (MRNA) settling at $33.64, representing a -1.87% change from its previous close.
The S&P 500 added 0.5% on Thursday, July 17, 2025, notching a record closing high for the first time in a week as June retail ...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside ...
Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...
Moderna’s stock price has taken a beating over the past six months, shedding 33.6% of its value and falling to $26.85 per share. This was partly due to its softer quarterly results and may have ...
The S&P 500 added 0.5% on Wednesday, July 2, 2025, reaching a record-high close for the second time this week as the U.S.